Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer gains former Lilly oncology exec

Executive Summary

Pfizer taps Garry Nicholson to head its oncology franchise, the firm announces May 14. Nicholson, who served as Lilly's Executive Director of the U.S. Oncology Business Unit, will be senior VP and general manager of Pfizer's new Oncology Business Unit, which was established March 5 with plans to achieve double-digit growth globally for mature products (1"The Pink Sheet," March 10, 2008, p. 5)

You may also be interested in...

Pfizer Tasks “Established Products Unit” With Extending Life Of Mature Drugs

As Pfizer faces a future without several key blockbuster drugs, Lipitor among them, the company is setting out to extend the life of its mature franchises with the formation of a dedicated business unit for established brands

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.

CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus

Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts